Funk-Debleds P, et al. - This research entailed the elucidation of subsequent non-melanoma skin cancers (NMSC) in liver transplant recipients (LTR) with long follow-up. Additionally, researchers sought to contemplate the factors influencing it, including immunosuppressive regimen. In LTR, subsequent NMSCs were discovered to be very frequent. A reduction could be achieved in the subsequent NMSC through the conversion from CNI-based immunosuppressive regimen to mTORi/antimetabolite-based immunosuppressive regimen.

Methods

• The enrollment consisted of 98 LTR (76 male) with a personal post-transplant history of squamous-cell carcinoma (SCC), basal-cell carcinoma (BCC) or Bowen’s disease.
• Median follow-up of the enrollees was 12.4 years (range: 1.5-27.8) after liver transplantation.

Results

• As per the outcomes, the median follow-up after first NMSC was 6.4 years (range: 0.17-22.1).
• The development of 141 subsequent NMSC with a BCC/SCC ratio of 1.8:1 was noted in 52 (53.1%) patients.
• The actuarial risk of developing a second NMSC was disclosed to be 13.7% at 1 year, 28.4% at 2 years, 49.4% at 5 years, 65.7% at 10 years, and 88.4% at 15-years.
• In the multivariate analysis, phototype I-II (vs. III-IV) was discovered to be a predominant risk factor for second NMSC (HR: 2.556, 95%CI [1.45; 4.48], p=0.001).
• On the other hand, withdrawal of calcineurin inhibitors (CNI) was unveiled to be prominentky protective (HR: 0.358, 95%CI [0.142; 0.902], p=0.029).